Biohaven announced positive topline results from a pivotal phase 2/3 study evaluating rimegepant for the preventive treatment of episodic and chronic migraine in adults.
The FDA has accepted the resubmitted NDA for XaraColl® for the management of postsurgical pain after open inguinal hernia surgery.
Dr. Reddy’s Laboratories announced the availability of Naloxone Hydrochloride Injection, a therapeutic equivalent generic version of Narcan.
Biohaven announced that Nurtec™ ODT is now available for the acute treatment of migraine with or without aura in adults.
The FDA has accepted for review the NDA for Qtrypta™ (zolmitriptan intracutaneous microneedle system; Zosano Pharma) for the acute treatment of migraine.
Hikma Pharmaceuticals USA announced that the voluntary recall of Ketorolac Tromethamine Injection 30mg/mL vials has been extended to include additional lots.
The FDA has accepted for review the Biologics License Application (BLA) for tanezumab 2.5mg administered subcutaneously for moderate to severe OA pain.
The Food and Drug Administration (FDA) has approved Nurtec™ ODT (rimegepant; Biohaven) for the acute treatment of migraine with or without aura in adults.
The Food and Drug Administration has approved Vyepti (eptinezumab-jjmr; Lundbeck) for the preventive treatment of migraine in adults.
The FDA has approved an autoinjector device for Ajovy (fremanezumab-vfrm; Teva) injection for the preventive treatment of migraine in adults.
